Cite
Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419-e426doi: 10.1016/S2665-9913(21)00059-X.
Avouac, J., Drumez, E., Hachulla, E., Seror, R., Georgin-Lavialle, S., El Mahou, S., Pertuiset, E., Pham, T., Marotte, H., Servettaz, A., Domont, F., Chazerain, P., Devaux, M., Claudepierre, P., Langlois, V., Mekinian, A., Maria, A. T. J., Banneville, B., Fautrel, B., Pouchot, J., Thomas, T., Flipo, R. M., Richez, C. (2021). COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. The Lancet. Rheumatology, 3(6), e419-e426. https://doi.org/10.1016/S2665-9913(21)00059-X
Avouac, Jérôme, et al. "COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study." The Lancet. Rheumatology vol. 3,6 (2021): e419-e426. doi: https://doi.org/10.1016/S2665-9913(21)00059-X
Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo RM, Richez C. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25. PMID: 33786454; PMCID: PMC7993930.
Copy
Download .nbib